Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENO1 | P06733 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26271467 | 0.86 | EPHX2 (0.39) | EPHX2 | |
| SCHEMBL24397584 | 0.85 | ENO1 (0.36) | ENO1CA2JAK2JAK1TYK2 | |
| SCHEMBL24397537 | 0.85 | EPHX2 (0.35) | EPHX2SMN1; SMN2 | |
| SCHEMBL24397611 | 0.82 | CRBN (0.36) | — | |
| SCHEMBL24411661 | 0.73 | POLB (0.33) | EPHX2SMN1; SMN2 | |
| SCHEMBL26271448 | 0.70 | HPGD (0.46) | CA2CA12CA1CA9EPHX2 | |
| SCHEMBL24411659 | 0.70 | ALDH1A1 (0.35) | — | |
| SCHEMBL19172671 | 0.69 | CA2 (0.49) | CA2CA12CA1CA4CA9 | |
| SCHEMBL24397614 | 0.67 | ALDH1A1 (0.38) | — | |
| SCHEMBL24040332 | 0.67 | MEN1 (0.41) | ENO1CA2HRH3CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295222-A1 | Conjugation Reagents and Methods Using 1,2-Cyclohexanediones | Encodia, Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| US-11639366-B2 | Conjugation reagents and methods using 1,2-cyclohexanediones | Encodia, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20220144885-A1 | CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES | Encodia, Inc. (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2022094148-A1 | CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES | Encodia, Inc. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144885-A1 | CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES | TNNI3, CHD1, TNNT2 | ENO1 1838/4885CA2 2114/4885JAK2 4265/4885 |
| US-20230295222-A1 | Conjugation Reagents and Methods Using 1,2-Cyclohexanediones | TNNI3, CHD1, TNNT2 | ENO1 1838/4885CA2 2114/4885JAK2 4265/4885 |
| US-11639366-B2 | Conjugation reagents and methods using 1,2-cyclohexanediones | TNNI3, CHD1, TNNT2 | ENO1 1838/4885CA2 2114/4885JAK2 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.